A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
The MTA reported that the 1, 2, 3, 4, 5 and 6 trains are all facing delays due to a network communications issue impacting service in both directions, NBC New York reports.Transportationread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
US officials including Treasury Secretary Steven Mnuchin and White House economic adviser Larry Kudlow will host a meeting at the White House on Monday of semiconductor and...Technologyread more
Trump's constant berating of the Fed and its actions does not influence the central bank's decisions, Boston Fed's Eric Rosengren says.The Fedread more
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.Health and Scienceread more
CNBC's Jim Cramer fired back Thursday on comments from Mylan CEO Heather Bresch about pricing of the auto-injection device EpiPen.
"If you can get away with jacking things up and gouging it then you've got to do it," Cramer said on "Squawk on the Street, " "because the shareholders want it."
The scrutinized company announced Thursday it plans to increase access to its EpiPen, a lifesaving device for people with severe allergies. Mylan said it would make expansions to its already existing cost-cutting programs.
Shares of Mylan rose after the announcement.
Cramer, who says he uses a similar medication, has been critical of the pharmaceutical company and industry, saying in part that the companies will do whatever they can get away with in the system.
"As someone who is well-off-enough to have these ... and you don't need two, you need a store hold of them," he said. "This is one where you can get away with it. There's no competition, there is supposed to be competition."
He also briefly commented on Mylan's stock rise in early trading and whether or not the CEO's comments satisfied shareholders.
"Until the real Donald Trump tweets and says she should give it away, " he said. "And then [Hillary] Clinton tweets that 'I was unsatisfied.'"